HEALTH DECISION STRATEGIES, LLC

(c) HDS
COST EFFECTIVENESS MODEL
ON THE IMPACT OF PERSISTENCE
Beta Test -- Not for Official Use
Parameter estimates for cost-effectiveness model of the impact of persistence    
You can change values in yellow boxes, then hit "Submit"      
  GROUP A     GROUP B     GROUP C
Utility in 'non-persist' health state
Utility in 'non-persistent' health state
Utility in 'non-persistent' health state
Utility in 'persist' health state
Utility in 'persistent' health state
Utility in 'persistent' health state
Annual cost in 'non-persist' health state
Annual cost in 'non-persistent' health state
Annual cost in 'non-persistent' health state
Annual cost in 'persist' health state
Annual cost in 'persistent' health state
Annual cost in 'persistent' health state
Annual drug cost
Annual drug cost
Annual drug cost
Number of Pts
Number of Pts
Number of Pts
Time Period Years
Time Period Years
Time Period Years
'Non-persist' Deaths Pct/Yr
'Non-persist' Deaths Pct/Yr
'Non-persist' Deaths Pct/Yr
'Persist' Deaths Pct/Yr
'Persist' Deaths Pct/Yr
'Persist' Deaths Pct/Yr
  GROUP A     GROUP B     GROUP C
Enter value as exponent for linear or nonlinear "non-drug cost" curve -->.





Sample Graph of Cost versus Persistence

Sample Graph of Cost versus Persistence

References

1. Hughes D et al. Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations. Value in Health. 10(6):498-509, November/December 2007.

2. Hughes D et al. Accounting for Noncompliance in Pharmacoeconomic Evaluations. Pharmacoeconomics. 19(12):1185-1197, 2001.

3. Peterson AM, McGhan WF. Pharmacoeconomic Impact of Non-Compliance with Statins. Pharmacoeconomics. 23(1):13-25, 2005.

4. Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. The Economic Consequences of Noncompliance in Cardiovascular Disease and Related Conditions: a Literature Review. International Journal of Clinical Practice 62(2):338-351, 2008.



Powered By HDS